CC
ONCT

Caxton Corporation’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Caxton Corporation’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-356
Closed -$763K – 31
2018
Q2 		$763K Buy
356
+3
+0.8% +$7.61K 0.27% 14
2018
Q1 		$877K Sell
353
-96
-21% -$214K 0.95% 11
2017
Q4 		$799K Hold
449
– – 0.97% 9
2017
Q3 		$531K Buy
+449
New +$404K 0.54% 11

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Corporation's ONCT Position: Q3 2018 in Review

Caxton Corporation sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 356 shares — an estimated $763K sold.

Caxton Corporation first reported a position in ONCT in Q3 2017 and held it in 4 quarters. The position peaked at $877K in Q1 2018. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

  • Caxton Corporation reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Caxton Corporation sold 356 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $763K.
  • Caxton Corporation first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
  • Caxton Corporation's Oncternal Therapeutics, Inc. Common Stock position peaked at $877K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Caxton Corporation's 13F filing for Q3 2018, filed 14 Nov 2018.